8-K current report · filed Nov 2, 2026

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K Current Report: November 2, 2026

Item 3.01SUPN overview

Short answer

SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 3.01 (Notice of Delisting). Merger consummated November 2, 2026, ending Supernus common stock trading on Nasdaq.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 3.01 · Notice of Delisting

  • Merger consummated November 2, 2026, ending Supernus common stock trading on Nasdaq
  • Nasdaq delisting and Section 12(b) deregistration initiated through Form 25
  • Planned Form 15 filing would terminate Section 13 and 15(d) SEC reporting obligations
  • Shares will no longer trade on any national securities exchange, eliminating public-market liquidity for shareholders

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings

Get the next SUPN 8-K as it lands

Follow SUPN for push alerts, or ask the research agent what this filing means.